Compare TRVG & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | EOLS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.1M | 304.0M |
| IPO Year | N/A | 2018 |
| Metric | TRVG | EOLS |
|---|---|---|
| Price | $2.83 | $4.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.09 | ★ $17.40 |
| AVG Volume (30 Days) | 60.3K | ★ 1.5M |
| Earning Date | 02-03-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $644,489,844.00 | $285,823,000.00 |
| Revenue This Year | $18.54 | $13.70 |
| Revenue Next Year | $9.07 | $13.40 |
| P/E Ratio | $15.90 | ★ N/A |
| Revenue Growth | ★ 19.11 | 15.10 |
| 52 Week Low | $2.71 | $4.41 |
| 52 Week High | $5.83 | $17.12 |
| Indicator | TRVG | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 28.48 |
| Support Level | $2.75 | $4.56 |
| Resistance Level | $3.16 | $4.99 |
| Average True Range (ATR) | 0.11 | 0.26 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 20.71 | 2.40 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and All other countries.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.